The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.
Author: The Medical News
CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1
Researchers at the University of Cincinnati (UC) and Cincinnati Children’s Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.
Loyola offers corrective surgeries for adults with strabismus
Since she was a child, Katie Szymczak has had eyes that wandered. Her right eye, which was the worst, would look up and to the side, rather than straight ahead. Her husband affectionately called them “googly eyes.” But other people could be mean. “They…
Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
Cost of glaucoma revealed
The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.
Dexamethasone use during tonsillectomy not associated with excessive bleeding in children
Tonsillectomy is exceedingly common, with a reported increase in tonsillectomy rates in children younger than 15 years from 287,000 to 530,000 per year over the past decade. Although safe, adenotonsillectomy can result in significant complications, suc…
STAAR Surgical to participate in 88th Congress of the Society of Spanish Ophthalmologists
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it will be participating in the 88th Congress of the Society of Spanish Ophthalmologists being held in Barcelona from…
pSivida reports revenues of $699,000 for fourth quarter 2012
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.
Ohr commences Phase II clinical trial of Squalamine for wet-AMD
Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.
Valeant purchases QLT’s Visudyne
Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.
Structure and function combined is best for detecting, discriminating glaucoma
An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone,…
Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy
Weill Cornell Medical College’s ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.
Mathematical modeling can help treat several diseases
Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that conti…
Study uncovers why some HIV-positive people take long time to progress to full-blown AIDS
One of the big mysteries of AIDS is why some HIV-positive people take more than a decade to progress to full-blown AIDS, if they progress at all.
Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges
A small subset of patients with open-angle glaucoma (OAG) account for a large proportion of all glaucoma-related charges in the United States, according to new data published by researchers at the University of Michigan Kellogg Eye Center and Washingto…
Fifth Military Vision Research Symposium to take place from Sept. 18-20
Eye injuries in war have changed – and increased in number – as weapons, tactics, technology and strategies have evolved. Today’s soldiers face threats from explosive devices that cause extensive damage areas not protected by body armor. Military exper…
University of Rochester faculty member to receive Ant-nio Champalimaud Vision Award
David Williams, a faculty member of the University of Rochester’s Institute of Optics, director of its Center for Visual Science, and dean for research in Arts, Science, and Engineering, will receive the Ant-nio Champalimaud Vision Award at a ceremony …
Factors predictive of successful DME treatment revealed
The pretreatment central subfield thickness in the eyes of patients with diabetic macular edema is the strongest predictor of outcome after one year of treatment with ranibizumab, with a reduction linked to better visual acuity outcomes, report researc…
Readily available index provides practical landmarks for glaucoma patients
The mean deviation index, a widely understood metric for summarizing damage to an individuals’ visual field, could help physicians estimate practical landmarks in patients with glaucoma such as fitness to drive, report UK researchers.
Bioengineers design nanoparticles that can safely and predictably infiltrate deep into the brain
The brain is a notoriously difficult organ to treat, but Johns Hopkins researchers report they are one step closer to having a drug-delivery system flexible enough to overcome some key challenges posed by brain cancer and perhaps other maladies affecti…